Buhl S - Search Results

1

Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-α Independent Crohn Disease.

Steenholdt C, Coskun M, Buhl S, Bendtzen K, Ainsworth MA, Brynskov J, Nielsen OH. Steenholdt C, et al. Among authors: buhl s. Medicine (Baltimore). 2016 Apr;95(16):e3417. doi: 10.1097/MD.0000000000003417. Medicine (Baltimore). 2016. PMID: 27100432 Free PMC article. Clinical Trial.

2

Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial.

Buhl SS, Steenholdt C, Brynskov J, Thomsen OØ, Bendtzen K, Ainsworth MA. Buhl SS, et al. BMJ Open. 2014 Dec 18;4(12):e005887. doi: 10.1136/bmjopen-2014-005887. BMJ Open. 2014. PMID: 25524543 Free PMC article. Clinical Trial.

3

Systematic Information to Health-Care Professionals about Vaccination Guidelines Improves Adherence in Patients With Inflammatory Bowel Disease in Anti-TNFα Therapy.

Christensen KR, Steenholdt C, Buhl SS, Ainsworth MA, Thomsen OØ, Brynskov J. Christensen KR, et al. Among authors: buhl ss. Am J Gastroenterol. 2015 Nov;110(11):1526-32. doi: 10.1038/ajg.2015.162. Epub 2015 Jun 2. Am J Gastroenterol. 2015. PMID: 26032156

4

Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease.

Buhl S, Steenholdt C, Rasmussen M, Borghede MK, Brynskov J, Thomsen OØ, Ainsworth MA. Buhl S, et al. Inflamm Bowel Dis. 2017 Jul;23(7):1210-1217. doi: 10.1097/MIB.0000000000001117. Inflamm Bowel Dis. 2017. PMID: 28445244

5

Outcome of continued infliximab therapy in Crohn's disease patients with response but without remission after one year of infliximab - a retrospective cohort study.

Buhl S, Kristina Borghede M, Brynskov J, Steenholdt C, Rasmussen M, Andrew Ainsworth M. Buhl S, et al. Scand J Gastroenterol. 2018 Aug;53(8):930-937. doi: 10.1080/00365521.2018.1481519. Epub 2018 Jul 10. Scand J Gastroenterol. 2018. PMID: 29987951

6

Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease.

Buhl S, Dorn-Rasmussen M, Brynskov J, Ainsworth MA, Bendtzen K, Klausen PH, Bolstad N, Warren DJ, Steenholdt C. Buhl S, et al. Scand J Gastroenterol. 2020 Aug;55(8):884-890. doi: 10.1080/00365521.2020.1786852. Epub 2020 Jul 6. Scand J Gastroenterol. 2020. PMID: 32631131

7

Drug Levels Associated With Optimal Discrimination Between Remission and Nonremission and Comparison of Antibody Assays During First Year of Stable Infliximab Maintenance Therapy in Inflammatory Bowel Disease.

Dorn-Rasmussen M, Buhl S, Brynskov J, Bay JT, Bolstad N, Klausen TW, Warren DJ, Ainsworth MA, Steenholdt C. Dorn-Rasmussen M, et al. Among authors: buhl s. Ther Drug Monit. 2022 Apr 1;44(2):290-300. doi: 10.1097/FTD.0000000000000913. Ther Drug Monit. 2022. PMID: 34387220

8

A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients' and physicians' preferences and adherence.

Christensen KR, Steenholdt C, Buhl S, Brynskov J, Ainsworth MA. Christensen KR, et al. Among authors: buhl s. Scand J Gastroenterol. 2022 Mar;57(3):274-281. doi: 10.1080/00365521.2021.2002397. Epub 2021 Nov 13. Scand J Gastroenterol. 2022. PMID: 34779308 Review.

9

Fatigue is a systemic extraintestinal disease manifestation largely independent of disease activity, chronicity, and nutritional deficiencies in inflammatory bowel disease on biologics.

Christensen KR, Ainsworth MA, Steenholdt C, Buhl S, Skougaard M, Brynskov J, Jørgensen TS, Kristensen LE. Christensen KR, et al. Among authors: buhl s. Scand J Gastroenterol. 2022 Sep;57(9):1051-1057. doi: 10.1080/00365521.2022.2060049. Epub 2022 Apr 12. Scand J Gastroenterol. 2022. PMID: 35412932

10

Identifying and understanding disease burden in patients with inflammatory bowel disease.

Christensen KR, Ainsworth MA, Skougaard M, Steenholdt C, Buhl S, Brynskov J, Kristensen LE, Jørgensen TS. Christensen KR, et al. Among authors: buhl s. BMJ Open Gastroenterol. 2022 Oct;9(1):e000994. doi: 10.1136/bmjgast-2022-000994. BMJ Open Gastroenterol. 2022. PMID: 36302557 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

77 results

Search Page

Filters